https://www.reuters.com/article/health-coronavirus-pfizer-idUSKBN2670AO

13 0

FILE PHOTO: A sign is pictured outside Pfizer Headquarters in the Manhattan borough of New York City, New York, U.S., July 22, 2020. REUTERS/Carlo Allegri. (Reuters) - Pfizer Inc said on Tuesday participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study. Over 12,000 study participants had received a second dose of the vaccine, Pfizer executives said on an investor conference call. The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech. Pfizer said it was continuously scrutini... Full story

16 September

wait